STOCKS TELEGRAPH

Tag: ARWR Stock Price

  • Arrowhead (ARWR) Sees Stock Surge Following Strategic Collaboration

    Arrowhead (ARWR) Sees Stock Surge Following Strategic Collaboration

    As of the last check, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) stock was trading up 17.32% to $22.04, a remarkable increase on the charts. Announcement of its strategic license and partnership deal with Sarepta Therapeutics is propelling the surge. This agreement represents a major turning point in ARWR’s journey from development to commercialization and offers the firm substantial financial and strategic advantages.

    Terms of the ARWR’s Agreement

    Arrowhead (ARWR) would get an upfront payment of $825 million. This includes $500 million in cash and $325 million from Sarepta’s equity investment, 35% more than its ARWR’s current price.

    Arrowhead will also get $250 million in installment payments over five years, with the possibility of up to $300 million in near-term payments that are anticipated to be realized within the next year. In addition to royalties from commercial sales, Arrowhead might eventually collect milestone payments of up to $10 billion.

    Strategic Implications for Arrowhead

    The collaboration encompasses a range of clinical and preclinical programs targeting rare genetic diseases affecting the muscle, central nervous system (CNS), and lungs. Additionally, Sarepta will be able to choose up to six additional targets for Arrowhead to create with its in-house Targeted RNAi Molecule (TRiM) technology. This alliance bolsters Arrowhead’s capabilities in precision genetic medicine, aligning with Sarepta’s leadership in the field.

    Path to Commercialization and Future Prospects

    This partnership provides Arrowhead with crucial funding to expand its operations and develop its pipeline, with the company now focusing on advancing its investigational drug, plozasiran, for the treatment of familial chylomicronemia syndrome. Plozasiran is anticipated to be Arrowhead’s first commercial product, with a possible launch date of 2025, if the FDA approves it.

    By extending Arrowhead’s cash runway beyond 2028 and providing space for many potential medication launches, the purchase also guarantees the company’s financial stability. Sarepta CEO Doug Ingram has joined Arrowhead’s Board of Directors, contributing essential industry knowledge to help steer the business through this critical stage of development and expansion.

  • Is This Why The ARWR Stock Is Falling Premarket Session Today?

    Arrowhead Pharmaceuticals Inc. (ARWR) shares were down -17.73% at $69.90 at the last check in pre-market trading. Arrowhead stock closed the last session at $84.96, an increase of 2.58% or $2.14. ARWR stock traded between the price range of $82.20 and $86.01. ARWR traded 0.69 million shares, down from 0.79 million in its 50-day average daily volume.

    Within the last 12 months, ARWR shares have grown 92.39%, and within the last week, they have decreased -5.08%. A total of 9.72% has been gained by the ARWR stock over the last six months, and a total of 26.67% has been gained over the last three months. ARWR stock has fallen since the company announced a clinical trial would be halted.

    Which study has ARWR paused?

    Arrowhead Pharma is dedicated to developing medicines that silence genetic causes of intractable diseases. ARWR therapies induce rapid, deep, and durable gene knockdown by triggering the RNA interference mechanism with a broad range of RNA chemistry options and efficient delivery methods. Living cells use RNA interference, or RNAi, to suppress the expression of certain genes, thereby affecting certain proteins. These natural pathways of gene silencing are utilized by ARWR’s RNAi-based therapeutics.

    Arrowhead today notified regulatory agencies, institutional review boards, and investigators it would be voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, effective immediately.

    • It was an investigational RNA interference (RNAi) therapy being developed by ARWR for patients with cystic fibrosis (CF).
    • ARWR made the decision after receiving a preliminary update from an ongoing chronic toxicology study that included unexpected evidence of lung inflammation in rats.
    • Until additional results from both the chronic rat toxicology study and an additional chronic primate toxicology study are reported, ARWR instructed investigators not to conduct new screening, enrollment, or further dosing of investigational ARO-ENaC.

    Arrowhead this week said its Phase 2b clinical study of ARO-ANG3 has dosed its first patient, an announcement that follows the first patient dosed in AROANG3-2001. ARWR was developing RNA interference (RNAi) therapeutics as a treatment for mixed dyslipidemia patients.

    How did the ARWR CEO respond?

    The CEO and president of Arrowhead Pharmaceuticals (ARWR), Christopher Anzalone, Ph.D., stated that although this is difficult news for cystic fibrosis patients who need new therapies, ARWR has an obligation to ensure that those enrolled in our clinical trials remain safe at all times.

    Arrowhead Pharmaceuticals (ARWR) believes that it needs to better understand the results from the chronic toxicology study in rats before proceeding with the current Phase 1 study, even though the data may not directly relate to the safety of continuing to treat patients.

    ARWR’s pulmonary program may have to wait a bit because of this, but it comes with drug development. ARWR will analyze the long-term toxicology data it receives as soon as possible to determine how it might affect ARO-ENaC and the patients it intends to serve.